Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease

NCT04691661 is registered in ClinicalTrials.gov with Il-Yang Pharm. Co., Ltd. as lead sponsor.

NCT NCT04691661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04691661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease
Lead sponsor
Il-Yang Pharm. Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 9, 2021
Completion date
April 30, 2027
Enrollment
43 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease